Skip to main content

COMPUTE BEYOND NATURE

Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology.

Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space to design new molecular structures not found in nature.

Our molecules open the door to a brand-new class of medicine with enhanced drug-like properties. We are harnessing the power of our platform to go after previously impossible targets in an array of indications.

We aim to boldly transform the ability to create new medicines, to leverage computing to make high throughput screening obsolete, and to ultimately cure disease. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners.

Read the
latest news

Vilya news and publications on macrocycle design, therapies and more.

1

6/4/2024

Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines

2

4/25/2024

Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles

3

10/17/2023

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

4

2/26/2023

bioRxiv: Cyclic peptide structure prediction and design using AlphaFold

PUSH BOUNDARIES

Motivated by
curing disease?

JOIN VILYA
Vilya
COMPUTE BEYOND NATURE
JOIN US

Connect

© 2024 Vilya, Inc.